CD19 and hematopoietic and lymphoid cell neoplasm: This phenomenon has been observed, e.g., for CD19 CAR-T cell therapy in patients with hematopoietic cancers and is likely to be a more significant challenge in solid tumors due to their pronounced heterogeneity.99